Defects in Thymic Development: DiGeorge/CHARGE/Chromosome 22q11.2 Deletion

Stiehm's Immune Deficiencies

Volumn , Issue , 2014, Pages 221-242

  Markert, M Louise ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

22q11.2 deletion syndrome; CHARGE syndrome; DiGeorge syndrome; Primary immunodeficiency; T cell deficiency

Indexed keywords

EID: 84943424916     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-405546-9.00008-X     Document Type: Chapter

References (142)

1. DiGeorge A.M. Maldescent of the thymus. Pediatr Pathol 1994, 14(1):9-80. 178; author reply.
2. Conley M.E., Beckwith J.B., Mancer J.F., Tenckhoff L. The spectrum of the DiGeorge syndrome. J Pediatr 1979, 94(6):883-890.
3. Hong R. The DiGeorge anomaly. Immunodefic Rev 1991, 3(1):1-14.
4. Barrett D.J., Ammann A.J., Wara D.W., Cowan M.J., Fisher T.J., Stiehm E.R. Clinical and immunologic spectrum of the DiGeorge syndrome. J Clin Lab Immunol 1981, 6(1):1-6.
5. Sullivan K.E. Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/velocardiofacial syndrome. Immunol Allergy Clin North Am 2008, 28(2):353-366.
6. Monteiro F.P., Vieira T.P., Sgardioli I.C., Molck M.C., Damiano A.P., Souza J., et al. Defining new guidelines for screening the 22q11.2 deletion based on a clinical and dysmorphologic evaluation of 194 individuals and review of the literature. Eur J Pediatr 2013, 172(7):927-945.
7. Brauner R., Le Harivel de Gonneville A., Kindermans C., Le Bidois J., Prieur M., Lyonnet S., et al. Parathyroid function and growth in 22q11.2 deletion syndrome. J Pediatr 2003, 142(5):504-508.
8. McDonald-McGinn D.M., Sullivan K.E. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine 2011, 90(1):1-18.
9. Ryan A.K., Goodship J.A., Wilson D.I., Philip N., Levy A., Seidel H., et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet 1997, 34(10):798-804.
10. McLean-Tooke A., Barge D., Spickett G.P., Gennery A.R. Immunologic defects in 22q11.2 deletion syndrome. J Allergy Clin Immunol 2008, 122(2):362-367. 7. e1-4.
11. Bergman J.E., Janssen N., Hoefsloot L.H., Jongmans M.C., Hofstra R.M., van Ravenswaaij-Arts C.M. CHD7 mutations and CHARGE syndrome: the clinical implications of an expanding phenotype. J Med Genet 2011, 48(5):334-342.
12. Blake K.D., Salem-Hartshorne N., Daoud M.A., Gradstein j. Adolescent and adult issues in CHARGE syndrome. Clin Pediatr 2005, 44(2):151-159.
13. Lin A.E., Chin A.J., Devine W., Park S.C., Zackai E. The pattern of cardiovascular malformation in the CHARGE association. Am J Dis Child 1987, 141(9):1010-1013.
14. Aramaki M., Udaka T., Kosaki R., Makita Y., Okamoto N., Yoshihashi H., et al. Phenotypic spectrum of CHARGE syndrome with CHD7 mutations. J Pediatr 2006, 148(3):410-414.
15. Vissers L.E., van Ravenswaaij C.M., Admiraal R., Hurst J.A., de Vries B.B., Janssen I.M., et al. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 2004, 36(9):955-957.
16. Blake K.D., Davenport S.L., Hall B.D., Hefner M.A., Pagon R.A., Williams M.S., et al. CHARGE association: an update and review for the primary pediatrician. Clin Pediatr 1998, 37(3):159-173.
17. Wyse R.K., al-Mahdawi S., Burn J., Blake K. Congenital heart disease in CHARGE association. Pediatr Cardiol 1993, 14(2):75-81.
18. Issekutz K.A., Graham J.M., Prasad C., Smith I.M., Blake K.D. An epidemiological analysis of CHARGE syndrome: preliminary results from a Canadian study. Am J Med Genet 2005, 133A(3):309-317.
19. Stromland K., Sjogreen L., Johansson M., Ekman Joelsson B.M., Miller M., Danielsson S., et al. CHARGE association in Sweden: malformations and functional deficits. Am J Med Genet 2005, 133(3):331-339.
20. Choi J.H., Shin Y.L., Kim G.H., Seo E.J., Kim Y., Park I.S., et al. Endocrine manifestations of chromosome 22q11.2 microdeletion syndrome. Horm Res 2005, 63(6):294-299.
21. Chinen J., Rosenblatt H.M., Smith E.O., Shearer W.T., Noroski L.M. Long-term assessment of T-cell populations in DiGeorge syndrome. J Allergy Clin Immunol 2003, 111(3):573-579.
22. Sanlaville D., Etchevers H.C., Gonzales M., Martinovic J., Clement-Ziza M., Delezoide A.L., et al. Phenotypic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations correlates with expression during human development. J Med Genet 2006, 43(3):211-217.
23. Kim H.G., Layman L.C. The role of CHD7 and the newly identified WDR11 gene in patients with idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Mol Cell Endocrinol 2011, 346(1-2):74-83.
24. Fine S.E., Weissman A., Gerdes M., Pinto-Martin J., Zackai E.H., McDonald-McGinn D.M., et al. Autism spectrum disorders and symptoms in children with molecularly confirmed 22q11.2 deletion syndrome. J Autism Dev Disord 2005, 35(4):461-470.
25. Vorstman J.A., Morcus M.E., Duijff S.N., Klaassen P.W., Heineman-de Boer J.A., Beemer F.A., et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J Am Acad Child Adolesc Psychiatry 2006, 45(9):1104-1113.
26. Eliez S. Autism in children with 22q11.2 deletion syndrome. J Am Acad Child Adolesc Psychiatry 2007, 46(4):433-434. author reply 4-4.
27. Drew L.J., Crabtree G.W., Markx S., Stark K.L., Chaverneff F., Xu B., et al. The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders. Int J Dev Neurosci 2011, 29(3):259-281.
28. Bassett A.S., Chow E.W., Husted J., Weksberg R., Caluseriu o., Webb G.D., et al. Clinical features of 78 adults with 22q11 deletion syndrome. Am J Med Genet 2005, 138(4):307-313.
29. Forbes B.J., Binenbaum G., Edmond J.C., DeLarato N., McDonald-McGinn D.M., Zackai E.H. Ocular findings in the chromosome 22q11.2 deletion syndrome. J AAPOS 2007, 11(2):179-182.
30. Persson C., Friman V., Oskarsdottir S., Jonsson R. Speech and hearing in adults with 22q11.2 deletion syndrome. Am J Med Genet 2012, 158A(12):3071-3079.
31. Dyce O., McDonald-McGinn D., Kirschner R.E., Zackai E., Young K., Jacobs I.N. Otolaryngologic manifestations of the 22q11.2 deletion syndrome. Arch Otolaryngol-Head Neck Surg 2002, 128(12):1408-1412.
32. Klingberg G., Oskarsdottir S., Johannesson E.L., Noren J.G. Oral manifestations in 22q11 deletion syndrome. Int J Paediatr Dent 2002, 12(1):14-23.
33. Digilio M.C., Giannotti A., Castro M., Colistro F., Ferretti F., Marino B., et al. Screening for celiac disease in patients with deletion 22q11.2 (DiGeorge/velo-cardio-facial syndrome). Am J Med Genet 2003, 121A(3):286-288.
34. Jawad A.F., McDonald-Mcginn D.M., Zackai E., Sullivan K.E. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr 2001, 139(5):715-723.
35. Lawrence S., McDonald-McGinn D.M., Zackai E., Sullivan K.E. Thrombocytopenia in patients with chromosome 22q11.2 deletion syndrome. J Pediatr 2003, 143(2):277-278.
36. de Lonlay-Debeney P., Cormier-Daire V., Amiel J., Abadie V., Odent S., Paupe A., et al. Features of DiGeorge syndrome and CHARGE association in five patients. J Med Genet 1997, 34(12):986-989.
37. Rope A.F., Cragun D.L., Saal H.M., Hopkin R.J. DiGeorge anomaly in the absence of chromosome 22q11.2 deletion. J Pediatr 2009, 155(4):560-565.
38. Markert M.L., Alexieff M.J., Li j., Sarzotti M., Ozaki D.A., Devlin B.H., et al. Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome. Blood 2004, 104(8):2574-2581.
39. Markert M.L., Boeck A., Hale L.P., Kloster A.L., McLaughlin T.M., Batchvarova M.N., et al. Transplantation of thymus tissue in complete DiGeorge syndrome. N Engl J Med 1999, 341(16):1180-1189.
40. Markert M.L., Devlin B.H., Alexieff M.J., Li J., McCarthy E.A., Gupton S.E., et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood 2007, 109(10):4539-4547.
41. Markert M.L., Devlin B.H., McCarthy E.A. Thymus transplantation. Clin Immunol 2010, 135(2):236-246.
42. Markert M.L., Sarzotti M., Ozaki D.A., Sempowski G.D., Rhein M.E., Hale L.P., et al. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood 2003, 102(3):1121-1130.
43. Gennery A.R., Slatter M.A., Rice J., Hoefsloot L.H., Barge D., McLean-Tooke A., et al. Mutations in CHD7 in patients with CHARGE syndrome cause T-B+ natural killer cell+severe combined immune deficiency and may cause Omenn-like syndrome. Clin Exp Immunol 2008, 153(1):75-80.
44. Writzl K., Cale C.M., Pierce C.M., Wilson L.C., Hennekam R.C. Immunological abnormalities in CHARGE syndrome. Eur J Med Genet 2007, 50(5):338-345.
45. Sanka M., Tangsinmankong N., Loscalzo M., Sleasman J.W., Dorsey M.J. Complete DiGeorge syndrome associated with CHD7 mutation. J Allergy Clin Immunol 2007, 120(4):952-954.
46. Verloes A. Updated diagnostic criteria for CHARGE syndrome: a proposal. Am J Med Genet 2005, 133A(3):306-308.
47. Pagon R.A., Graham J.M., Zonana J., Yong S.L. Coloboma, congenital heart disease, and choanal atresia with multiple anomalies: CHARGE association. J Pediatr 1981, 99(2):223-227.
48. Lalani SR, Hefner MA, Belmont JW, Davenport SLH. CHARGE syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews. Seattle, WA; 1993.
49. Wang R., Martinez-Frias M.L., Graham J.M. Infants of diabetic mothers are at increased risk for the oculo-auriculo-vertebral sequence: a case-based and case-control approach. J Pediatr 2002, 141(5):611-617.
50. Farley A.M., Morris L.X., Vroegindeweij E., Depreter M.L., Vaidya H., Stenhouse F.H., et al. Dynamics of thymus organogenesis and colonization in early human development. Development 2013, 140(9):2015-2026.
51. Gardiner J.R., Jackson A.L., Gordon J., Lickert H., Manley N.R., Basson M.A. Localised inhibition of FGF signalling in the third pharyngeal pouch is required for normal thymus and parathyroid organogenesis. Development 2012, 139(18):3456-3466.
52. Grevellec A., Tucker A.S. The pharyngeal pouches and clefts: development, evolution, structure and derivatives. Semin Cell Dev Biol 2010, 21(3):325-332.
53. Hutson M.R., Kirby M.L. Model systems for the study of heart development and disease. Cardiac neural crest and conotruncal malformations. Semin Cell Dev Biol 2007, 18(1):101-110.
54. Keyte A., Hutson M.R. The neural crest in cardiac congenital anomalies. Differentiation 2012, 84(1):25-40.
55. Papangeli I., Scambler P.J. Tbx1 genetically interacts with the transforming growth factor-beta/bone morphogenetic protein inhibitor Smad7 during great vessel remodeling. Circ Res 2013, 112(1):90-102.
56. Thomas R.A., Landing B.H., Wells T.R. Embryologic and other developmental considerations of thirty-eight possible variants of the DiGeorge anomaly. Am J Med Genet 1987, 3(Suppl.):43-66.
57. Devriendt K., Fryns J.P., Mortier G., van Thienen M.N., Keymolen K. The annual incidence of DiGeorge/velocardiofacial syndrome. J Med Genet 1998, 35(9):789-790.
58. Goodship J., Cross I., LiLing J., Wren C. A population study of chromosome 22q11 deletions in infancy. Arch Dis Child 1998, 79(4):348-351.
59. Tezenas Du Montcel S., Mendizabai H., Ayme S., Levy A., Philip N. Prevalence of 22q11 microdeletion. J Med Genet 1996, 33(8):719.
60. Shprintzen R.J. Velo-cardio-facial syndrome: 30 years of study. Dev Disabil Res Rev 2008, 14(1):3-10.
61. Shaikh T.H., O'Connor R.J., Pierpont M.E., McGrath J., Hacker A.M., Nimmakayalu M., et al. Low copy repeats mediate distal chromosome 22q11.2 deletions: sequence analysis predicts breakpoint mechanisms. Genome Res 2007, 17(4):482-491.
62. Michaelovsky E., Frisch A., Carmel M., Patya M., Zarchi o., Green T., et al. Genotype-phenotype correlation in 22q11.2 deletion syndrome. BMC Med Genet 2012, 13:122.
63. Digilio M.C., Angioni A., De Santis M., Lombardo A., Giannotti A., Dallapiccola B., et al. Spectrum of clinical variability in familial deletion 22q11.2: from full manifestation to extremely mild clinical anomalies. Clin Genet 2003, 63(4):308-313.
64. Delio M., Guo T., McDonald-McGinn D.M., Zackai E., Herman S., Kaminetzky M., et al. Enhanced maternal origin of the 22q11.2 deletion in velocardiofacial and DiGeorge syndromes. Am J Hum Genet 2013, 92(3):439-447.
65. Lindsay E.A., Vitelli F., Su H., Morishima M., Huynh T., Pramparo T., et al. Tbx1 haploinsufficieny in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 2001, 410(6824):97-101.
66. Arnold J.S., Braunstein E.M., Ohyama T., Groves A.K., Adams J.C., Brown M.C., et al. Tissue-specific roles of Tbx1 in the development of the outer, middle and inner ear, defective in 22q11DS patients. Hum Mol Genet 2006, 15(10):1629-1639.
67. Fagman H., Liao J., Westerlund J., Andersson L., Morrow B.E., Nilsson M. The 22q11 deletion syndrome candidate gene Tbx1 determines thyroid size and positioning. Hum Mol Genet 2007, 16(3):276-285.
68. Verhagen J.M., Diderich K.E., Oudesluijs G., Mancini G.M., Eggink A.J., Verkleij-Hagoort A.C., et al. Phenotypic variability of atypical 22q11.2 deletions not including TBX1. Am J Med Genet 2012, 158A(10):2412-2420.
69. Conti E., Grifone N., Sarkozy A., Tandoi C., Marino B., Digilio M.C., et al. DiGeorge subtypes of nonsyndromic conotruncal defects: evidence against a major role of TBX1 gene. Eur J Hum Genet 2003, 11(4):349-351.
70. Gothelf D., Eliez S., Thompson T., Hinard C., Penniman L., Feinstein C., et al. COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 2005, 8(11):1500-1502.
71. Renick S.E., Kleven D.T., Chan J., Stenius K., Milner T.A., Pickel V.M., et al. The mammalian brain high-affinity L-proline transporter is enriched preferentially in synaptic vesicles in a subpopulation of excitatory nerve terminals in rat forebrain. J Neurosci 1999, 19(1):21-33.
72. Paterlini M., Zakharenko S.S., Lai W.S., Qin J., Zhang H., Mukai J., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 2005, 8(11):1586-1594.
73. Xu B., Hsu P.K., Stark K.L., Karayiorgou M., Gogos J.A. Derepression of a neuronal inhibitor due to miRNA dysregulation in a schizophrenia-related microdeletion. Cell 2013, 152(1-2):262-275.
74. de la Morena M.T., Eitson J.L., Dozmorov I.M., Belkaya S., Hoover A.R., Anguiano E., et al. Signature MicroRNA expression patterns identified in humans with 22q11.2 deletion/DiGeorge syndrome. Clin Immunol 2013, 147(1):11-22.
75. Brzustowicz L.M., Bassett A.S. miRNA-mediated risk for schizophrenia in 22q11.2 deletion syndrome. Front Genet 2012, 3:291.
76. Janssen N., Bergman J.E., Swertz M.A., Tranebjaerg L., Lodahl M., Schoots J., et al. Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat 2012, 33(8):1149-1160.
77. Bergman J.E., Janssen N., van der Sloot A.M., de Walle H.E., Schoots J., Rendtorff N.D., et al. A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome. Hum Mutat 2012, 33(8):1251-1260.
78. Pauli S., von Velsen N., Burfeind P., Steckel M., Manz J., Buchholz A., et al. CHD7 mutations causing CHARGE syndrome are predominantly of paternal origin. Clin Genet 2012, 81(3):234-239.
79. Shearer W.T., Rosenblatt H.M., Gelman R.S., Oyomopito R., Plaeger S., Stiehm E.R., et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003, 112(5):973-980.
80. Piliero L.M., Sanford A.N., McDonald-McGinn D.M., Zackai E.H., Sullivan K.E. T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome. Blood 2004, 103(3):1020-1025.
81. Cancrini C., Romiti M.L., Finocchi A., Di Cesare S., Ciaffi P., Capponi C., et al. Post-natal ontogenesis of the T-cell receptor CD4 and CD8 Vbeta repertoire and immune function in children with DiGeorge syndrome. J Clin Immunol 2005, 25(3):265-274.
82. Finocchi A., Di Cesare S., Romiti M.L., Capponi C., Rossi P., Carsetti R., et al. Humoral immune responses and CD27+ B cells in children with DiGeorge syndrome (22q11.2 deletion syndrome). Pediatr Allergy Immunol 2006, 17(5):382-388.
83. Pierdominici M., Marziali M., Giovannetti A., Oliva A., Rosso R., Marino B., et al. T cell receptor repertoire and function in patients with DiGeorge syndrome and velocardiofacial syndrome. Clin Exp Immunol 2000, 121(1):127-132.
84. Pierdominici M., Mazzetta F., Caprini E., Marziali M., Digilio M.C., Marino B., et al. Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Exp Immunol 2003, 132(2):323-331.
85. Sediva A., Bartunkova J., Zachova R., Polouckova A. Early development of immunity in diGeorge syndrome. Med Sci Monit 2005, 11(4):CR182-CR187.
86. Zemble R., Luning Prak E., McDonald K., McDonald-McGinn D., Zackai E., Sullivan K. Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Immunol 2010, 136(3):409-418.
87. Sullivan K.E., McDonald-McGinn D., Zackai E.H. CD4(+) CD25(+) T-cell production in healthy humans and in patients with thymic hypoplasia. Clin Diagn Lab Immunol 2002, 9(5):1129-1131.
88. Gennery A.R., Barge D., O'Sullivan J.J., Flood T.J., Abinun M., Cant A.J. Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome. Arch Dis Child 2002, 86(6):422-425.
89. Smith C.A., Driscoll D.A., Emanuel B.S., McDonald-McGinn D.M., Zackai E.H., Sullivan K.E. Increased prevalence of immunoglobulin A deficiency in patients with the chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Diagn Lab Immunol 1998, 5(3):415-417.
90. Davis C.M., Kancherla V.S., Reddy A., Chan W., Yeh H.W., Noroski L.M., et al. Development of specific T-cell responses to Candida and tetanus antigens in partial DiGeorge syndrome. J Allergy Clin Immunol 2008, 122(6):1194-1199.
91. Theodoropoulos D.S. Immune deficiency in CHARGE association. Clin Med Res 2003, 1(1):43-48.
92. McDonald-McGinn D.M., Reilly A., Wallgren-Pettersson C., Hoyme H.E., Yang S.P., Adam M.P., et al. Malignancy in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Am J Med Genet 2006, 140(8):906-909.
93. Van Mierop L.H., Kutsche L.M. Cardiovascular anomalies in DiGeorge syndrome and importance of neural crest as a possible pathogenetic factor. Am J Cardiol 1986, 58(1):133-137.
94. Peyvandi S., Lupo P.J., Garbarini J., Woyciechowski S., Edman S., Emanuel B.S., et al. 22q11.2 deletions in patients with conotruncal defects: data from 1,610 consecutive cases. Pediatr Cardiol 2013, 34(7):1687-1694.
95. Eberle P., Berger C., Junge S., Dougoud S., Buchel E.V., Riegel M., et al. Persistent low thymic activity and non-cardiac mortality in children with chromosome 22q11.2 microdeletion and partial DiGeorge syndrome. Clin Exp Immunol 2009, 155(2):189-198.
96. Taylor S.C., Morris G., Wilson D., Davies S.J., Gregory J.W. Hypoparathyroidism and 22q11 deletion syndrome. Arch Dis Child 2003, 88(6):520-522.
97. Kar P.S., Ogoe B., Poole R., Meeking D. Di-George syndrome presenting with hypocalcaemia in adulthood: two case reports and a review. J Clin Pathol 2005, 58(6):655-657.
98. Lewandowski K.E., Shashi V., Berry P.M., Kwapil T.R. Schizophrenic-like neurocognitive deficits in children and adolescents with 22q11 deletion syndrome. Am J Med Genet B Neuropsychiatr Genet 2007, 144(1):27-36.
99. Swillen A., Devriendt K., Legius E., Eyskens B., Dumoulin M., Gewillig M., et al. Intelligence and psychosocial adjustment in velocardiofacial syndrome: a study of 37 children and adolescents with VCFS. J Med Genet 1997, 34(6):453-458.
100. Moss E.M., Batshaw M.L., Solot C.B., Gerdes M., McDonald-McGinn D.M., Driscoll D.A., et al. Psychoeducational profile of the 22q11.2 microdeletion: A complex pattern. J Pediatr 1999, 134(2):193-198.
101. Davenport S.L., Hefner M.A., Mitchell J.A. The spectrum of clinical features in CHARGE syndrome. Clin Genet 1986, 29(4):298-310.
102. Glaser B., Mumme D.L., Blasey C., Morris M.A., Dahoun S.P., Antonarakis S.E., et al. Language skills in children with velocardiofacial syndrome (deletion 22q11.2). J Pediatr 2002, 140(6):753-758.
103. Dionne G., Boivin M., Seguin J.R., Perusse D., Tremblay R.E. Gestational diabetes hinders language development in offspring. Pediatrics 2008, 122(5):e1073-e1079.
104. DeBoer T., Wewerka S., Bauer P.J., Georgieff M.K., Nelson C.A. Explicit memory performance in infants of diabetic mothers at 1 year of age. Dev Med Child Neurol 2005, 47(8):525-531.
105. Deregnier R.A., Nelson C.A., Thomas K.M., Wewerka S., Georgieff M.K. Neurophysiologic evaluation of auditory recognition memory in healthy newborn infants and infants of diabetic mothers. J Pediatr 2000, 137(6):777-784.
106. Van Aken K., De Smedt B., Van Roie A., Gewillig M., Devriendt K., Fryns J.P., et al. Motor development in school-aged children with 22q11 deletion (velocardiofacial/DiGeorge syndrome). Dev Med Child Neurol 2007, 49(3):210-213.
107. Jansen P.W., Duijff S.N., Beemer F.A., Vorstman J.A., Klaassen P.W., Morcus M.E., et al. Behavioral problems in relation to intelligence in children with 22q11.2 deletion syndrome: a matched control study. Am J Med Genet 2007, 143(6):574-580.
108. Debbane M., Glaser B., David M.K., Feinstein C., Eliez S. Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: Neuropsychological and behavioral implications. Schizophr Res 2006, 84(2-3):187-193.
109. Gothelf D., Feinstein C., Thompson T., Gu E., Penniman L., Van Stone E., et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry 2007, 164(4):663-669.
110. Nishina S., Kosaki R., Yagihashi T., Azuma N., Okamoto N., Hatsukawa Y., et al. Ophthalmic features of CHARGE syndrome with CHD7 mutations. Am J Med Genet 2012, 158A(3):514-518.
111. Markert M.L., Majure M., Harville T.O., Hulka G., Oldham K. Severe laryngomalacia and bronchomalacia in DiGeorge syndrome and CHARGE association. Pediatr Pulmonol 1997, 24(5):364-369.
112. Oskarsdottir S., Vujic M., Fasth A. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Arch Dis Child 2004, 89(2):148-151.
113. Scuccimarri R., Rodd C. Thyroid abnormalities as a feature of DiGeorge syndrome: a patient report and review of the literature. J Pediatr Endocrinol Metab 1998, 11(2):273-276.
114. Kawame H., Adachi M., Tachibana K., Kurosawa K., Ito F., Gleason M.M., et al. Graves' disease in patients with 22q11.2 deletion. J Pediatr 2001, 139(6):892-895.
115. Ham Pong A.J., Cavallo A., Holman G.H., Goldman A.S. DiGeorge syndrome: long-term survival complicated by Graves disease. J Pediatr 1985, 106(4):619-620.
116. Brown J.J., Datta V., Browning M.J., Swift P.G. Graves' disease in DiGeorge syndrome: patient report with a review of endocrine autoimmunity associated with 22q11.2 deletion. J Pediatr Endocrinol Metab 2004, 17(11):1575-1579.
117. Segni M., Zimmerman D. Autoimmune hyperthyroidism in two adolescents with DiGeorge/velocardiofacial syndrome (22q11 deletion). Eur J Pediatr 2002, 161(4):233-234.
118. DePiero A.D., Lourie E.M., Berman B.W., Robin N.H., Zinn A.B., Hostoffer R.W. Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome. J Pediatr 1997, 131(3):484-486.
119. Pinchas-Hamiel o., Mandel M., Engelberg S., Passwell J.H. Immune hemolytic anemia, thrombocytopenia and liver disease in a patient with DiGeorge syndrome. Isr J Med Sci 1994, 30(7):530-532.
120. Sullivan K.E., McDonald-McGinn D.M., Driscoll D.A., Zmijewski C.M., Ellabban A.S., Reed L., et al. Juvenile rheumatoid arthritis-like polyarthritis in chromosome 22q11.2 deletion syndrome (DiGeorge anomalad/velocardiofacial syndrome/conotruncal anomaly face syndrome). Arthritis Rheum 1997, 40(3):430-436.
121. Davies K., Stiehm E.R., Woo P., Murray K.J. Juvenile idiopathic polyarticular arthritis and IgA deficiency in the 22q11 deletion syndrome. J Rheumatol 2001, 28(10):2326-2334.
122. Rasmussen S.A., Williams C.A., Ayoub E.M., Sleasman J.W., Gray B.A., Bent-Williams A., et al. Juvenile rheumatoid arthritis in velo-cardio-facial syndrome: coincidence or unusual complication?. Am J Med Genet 1996, 64(4):546-550.
123. Verloes A., Curry C., Jamar M., Herens C., O'Lague P., Marks J., et al. Juvenile rheumatoid arthritis and del(22q11) syndrome: a non-random association. J Med Genet 1998, 35(11):943-947.
124. Staple L., Andrews T., McDonald-McGinn D., Zackai E., Sullivan K.E. Allergies in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome) and patients with chronic granulomatous disease. Pediatr Allergy Immunol 2005, 16(3):226-230.
125. Markert M.L., Hummell D.S., Rosenblatt H.M., Schiff S.E., Harville T.O., Williams L.W., et al. Complete DiGeorge syndrome: persistence of profound immunodeficiency. J Pediatr 1998, 132(1):15-21.
126. Maecker H.T., McCoy J.P., Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev 2012, 12(3):191-200.
127. Smith C.S., Schoder H., Yeung H.W. Thymic extension in the superior mediastinum in patients with thymic hyperplasia: potential cause of false-positive findings on 18F-FDG PET/CT. Am J Roentgenol 2007, 188(6):1716-1721.
128. Heimall J., Keller M., Saltzman R., Bunin N., McDonald-McGinn D., Zakai E., et al. Diagnosis of 22q11.2 deletion syndrome and artemis deficiency in two children with T-B-NK+ immunodeficiency. J Clin Immunol 2012, 32(5):1141-1144.
129. Markert M.L., Alexieff M.J., Li J., Sarzotti M., Ozaki D.A., Devlin B.H., et al. Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol 2004, 113(4):734-741.
130. Pirovano S., Mazzolari E., Pasic S., Albertini A., Notarangelo L.D., Imberti L. Impaired thymic output and restricted T-cell repertoire in two infants with immunodeficiency and early-onset generalized dermatitis. Immunol Lett 2003, 86(1):93-97.
131. Junker A.K., Chan K.W., Massing B.G. Clinical and immune recovery from Omenn syndrome after bone marrow transplantation. J Pediatr 1989, 114(4 Pt 1):596-600.
132. Ocejo-Vinyals J.G., Lozano M.J., Sanchez-Velasco P., Escribano de Diego J., Paz-Miguel J.E., Leyva-Cobian F. An unusual concurrence of graft versus host disease caused by engraftment of maternal lymphocytes with DiGeorge anomaly. Arch Dis Child 2000, 83(2):165-169.
133. Selim M.A., Markert M.L., Burchette J.L., Herman C.M., Turner J.W. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. J Cutan Pathol 2008, 35(4):380-385.
134. Markert M.L., Devlin B.H., Chinn I.K., McCarthy E.A. Thymus transplantation in complete DiGeorge anomaly. Immunol Res 2009, 44(1-3):61-70.
135. Vu Q.V., Wada T., Toma T., Tajima H., Maeda M., Tanaka R., et al. Clinical and immunophenotypic features of atypical complete DiGeorge syndrome. Pediatr Int 2013, 55(1):2-6.
136. Knutsen A.P., Baker M.W., Markert M.L. Interpreting low T-cell receptor excision circles in newborns with DiGeorge anomaly: importance of assessing naive T-cell markers. J Allergy Clin Immunol 2011, 128(6):1375-1376.
137. Junker A.K., Driscoll D.A. Humoral immunity in DiGeorge syndrome. J Pediatr 1995, 127(2):231-237.
138. Perez E.E., Bokszczanin A., McDonald-McGinn D., Zackai E.H., Sullivan K.E. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 2003, 112(4):e325.
139. Moylett E.H., Wasan A.N., Noroski L.M., Shearer W.T. Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity. Clin Immunol 2004, 112(1):106-112.
140. Azzari C., Gambineri E., Resti M., Moriondo M., Betti L., Saldias L.R., et al. Safety and immunogenicity of measles-mumps-rubella vaccine in children with congenital immunodeficiency (DiGeorge syndrome). Vaccine 2005, 23(14):1668-1671.
141. Waters V., Peterson K.S., LaRussa P. Live viral vaccines in a DiGeorge syndrome patient. Arch Dis Child 2007, 92(6):519-520.
142. Red Book: A Report of the Committee on Infectious Diseases 1994, American Academy of Pediatrics, Elk Grove Village, IL. L.K. Pickering (Ed.).